Big announcement

1. Pharmaceutical Kande: The company did not pose a national security risk to any country in the past, present, or future

$WUXI APPTEC (02359.HK)$A clarification notice was issued. The company has no human genomics business, nor does the company collect human genomics data in any of its current businesses. Furthermore, the company has no connection with any government or military organization. The company firmly believes that Pharmacovigant did not pose a national security risk to any country in the past, present, or future, so it should not be pre-defined as a “biotech company to pay attention to” in the draft. The company will continue to cooperate with consultants and communicate with parties involved in the draft legislation process. The content of the draft still needs further review and may be changed.

2. Pharmaceutical Biology: It is expected that there will be no significant adverse changes in the Group's business operations and financial situation

$WUXI BIO (02269.HK)$The announcement stated that it has noticed unusual fluctuations in stock prices and trading volume on the Stock Exchange recently. The company would like to clarify that the relevant draft law is still in its early stages, is still awaiting further review and changes by the US legislature, and has not yet been enacted into effect. The company has neither a human genomics business nor does it collect human genomic data in its various businesses. The Company wishes to emphasize that its business operations have always been steady and continue to advance in accordance with its annual and medium-term strategies. The management team is confident about the company's prospects and does not anticipate any significant adverse changes in the Group's business operations and financial situation.

3. Meitu's full cash plus IPO website Cool Network, involving an investment of 310 million yuan

$MEITU (01357.HK)$According to the announcement, the total cost of the acquisition of Kool.com's shares was US$39.64 million (approximately HK$310 million), including cash of US$171 million; and payment through the issuance of 52.99 million consideration shares, the issue price was $26,237, a premium of 14.57% over the previous trading day (2 days). After joining the group, Zhanku.com will have a huge synergy effect on the development of Meitu's imaging and design product business, particularly the construction of the Miracle Vision visual model ecosystem and moat.

4. IGG Yingxi: Last year's net profit was about HK$70 million, turning a year-on-year loss into a profit

$IGG (00799.HK)$Fa Yingxi expects to record a net profit of about 70 million yuan in 2023, compared with a loss of 500 million yuan in the previous year. Achieving losses was mainly achieved without the Group's two new strategies, “Doomsday: Last Survivors” and “Viking Rise”, which contributed more than 1 billion yuan in revenue to the Group; the APP business grew steadily, increasing revenue by more than 4 times; continuously optimizing the personnel structure to reduce costs and increase efficiency, reducing R&D expenses and administrative expenses by about 26%; and the investment business entered a harvest period.

5. Cansino Biology: Loss of control over the drug Cansino is treated as a joint venture

$CANSINOBIO (06185.HK)$It was announced that control over the drug Cansino was lost. On February 2, the company held 49.8% of Shangyao Kangxino's shares, and only held 3 seats among the 7 directors of Shangyao Kangxino, and no longer controls more than half of the shares or more than half of the board seats. As a result, Shangyao Cansino will no longer be recorded as an affiliate of the company and will be recorded as an associated company.

According to the terms of the concerted action agreement, it will automatically be terminated within 3 years from the date Shanghai Pharmaceutical Cansino obtains a business license or when Shanghai Pharmaceutical Cansino completes the production of a specific amount of COVID-19 vaccine. As of February 1, 2024, it has been three years since Shangyao Cansino obtained a business license, and the concerted action agreement was automatically terminated.

Earnings Report

$IGG (00799.HK)$Yingxi: Expected annual net profit of around HK$70 million

Operational data

$ZHENRO PPT (06158.HK)$The cumulative contract sales amount in January was about 619 million yuan, a year-on-year decrease of 54.4%

$TIMES CHINA (01233.HK)$: Contract sales in January were 532 million yuan, a year-on-year decrease of 37.56%

Important matters

$WUXI APPTEC (02359.HK)$: The company has never been, is, and will not pose a national security risk to any country

$WUXI BIO (02269.HK)$: It is anticipated that there will be no significant adverse changes in the Group's business operations and financial situation

$MEITU (01357.HK)$The entire cash+IPO website Cool Network involved 310 million yuan

$CANSINOBIO (06185.HK)$Loss of control over the drug Cancino is treated as a joint venture

$CMS (00867.HK)$A replacement agreement was signed with VFMCRP and Weijian Investment (Hong Kong) for the sucrose hydroxide chewable Viveray

Equity incentives

$JNCEC (00579.HK)$A total of 103 million share value-added rights were granted to 113 incentive recipients

Repurchase cancellation

$AIA (01299.HK)$On February 2, it cost HK$181 million to buy back 3 million shares

$HSBC HOLDINGS (00005.HK)$On February 1, it cost HK$128 million to repurchase 2.1 million shares

$XIAOMI-W (01810.HK)$4 million shares were repurchased at HK$49.42 million on February 2

$KUAISHOU-W (01024.HK)$On February 2, it spent HK$39.9976 million to buy back 99,600 shares

$COSCO SHIP HOLD (01919.HK)$On February 2, it cost HK$155.95 million to repurchase 1.908,000 shares

$KINGSOFT (03888.HK)$On February 2, 521,000 shares were repurchased at HK$10 million

edit/new